Maravai LifeSciences Holdings, Inc.
MRVI
$4.15
-$0.14-3.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 65.84M | 49.87M | 41.63M | 47.40M | 46.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.84M | 49.87M | 41.63M | 47.40M | 46.85M |
| Cost of Revenue | 32.14M | 35.32M | 35.98M | 39.63M | 39.13M |
| Gross Profit | 33.70M | 14.54M | 5.66M | 7.77M | 7.73M |
| SG&A Expenses | 29.09M | 30.38M | 35.40M | 38.58M | 39.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.12M | 69.50M | 75.22M | 83.09M | 83.58M |
| Operating Income | 720.00K | -19.63M | -33.59M | -35.69M | -36.73M |
| Income Before Tax | -6.53M | -63.01M | -45.15M | -74.13M | -52.69M |
| Income Tax Expenses | -151.00K | 6.00K | -92.00K | -4.29M | 162.00K |
| Earnings from Continuing Operations | -6.38M | -63.02M | -45.06M | -69.84M | -52.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.64M | 27.33M | 19.50M | 30.25M | 22.91M |
| Net Income | -3.73M | -35.68M | -25.56M | -39.59M | -29.95M |
| EBIT | 720.00K | -19.63M | -33.59M | -35.69M | -36.73M |
| EBITDA | 12.09M | -7.18M | -20.40M | -22.53M | -24.00M |
| EPS Basic | -0.03 | -0.25 | -0.18 | -0.27 | -0.21 |
| Normalized Basic EPS | 0.00 | 0.09 | -0.03 | 0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.25 | -0.18 | -0.27 | -0.21 |
| Normalized Diluted EPS | 0.00 | 0.09 | -0.03 | 0.02 | -0.02 |
| Average Basic Shares Outstanding | 146.43M | 145.07M | 144.68M | 144.24M | 143.43M |
| Average Diluted Shares Outstanding | 146.43M | 145.07M | 144.68M | 144.24M | 143.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |